Welcome to our dedicated page for Tivic Health Systems SEC filings (Ticker: TIVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for Tivic Health’s latest FDA milestones, patent updates, or cash-runway details inside a 10-K? Most investors wade through dozens of pages before spotting the numbers that explain how microcurrent bioelectronic devices like ClearUP are funded and approved. Our platform answers the exact questions you type—think “Tivic Health SEC filings explained simply� or “understanding Tivic Health SEC documents with AI”—and surfaces the answers in seconds.
Every Tivic Health quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained arrives on Stock Titan in real time, alongside AI-powered summaries that translate complex clinical data and supply-chain disclosures into plain language. Need alerts for Tivic Health insider trading Form 4 transactions? We stream Tivic Health Form 4 insider transactions real-time so you can monitor executive stock transactions before they move the market. Proxy worries? A single click opens the Tivic Health proxy statement executive compensation section, already highlighted by our expert analysis.
Whether you’re tracking R&D spend trends, studying revenue from bioelectronic medicine devices, or comparing insider buying patterns, our coverage includes every filing type—from S-1s that detail future capital raises to 13Ds that reveal new large holders. Stop scanning PDFs; start using Tivic Health earnings report filing analysis that pinpoints what drives this med-tech innovator’s valuation.
Tectonic Therapeutic, Inc. (Nasdaq: TECX) has filed a Form S-3 shelf registration that allows the company to issue up to $400 million of common stock, preferred stock, debt securities and/or warrants. The filing also includes a dedicated $100 million at-the-market (ATM) sales agreement with TD Securities (USA) LLC, giving management flexibility to raise capital "from time to time" as clinical milestones approach.
The prospectus reiterates Tectonic’s strategy of developing biologics that modulate GPCRs via its proprietary GEODe� platform. Lead asset TX45 (Fc-relaxin fusion) has completed a Phase 1a study showing good tolerability and a favourable PK/PD profile. In Part A of an ongoing Phase 1b hemodynamic trial in PH-HFpEF patients, TX45 achieved a 19% reduction in pulmonary capillary wedge pressure and a >30% PVR reduction in a severe sub-population, with no serious adverse events. Recruitment is under way for Part B (PH-HFrEF), and the 24-week placebo-controlled Phase 2 APEX trial dosed its first patient in October 2024; topline data are expected in 2026.
Second program TX2100, a VHH-Fc fusion for Hereditary Hemorrhagic Telangiectasia, entered IND-enabling studies in Q2 2025, with a Phase 1 start targeted for late 2025/early 2026. The company completed a reverse-merger with Legacy Tectonic in June 2024 and now qualifies as a smaller reporting company. Proceeds from any sales under the shelf will fund pipeline advancement, working capital and potential in-licensing.
As of 3 July 2025 the stock traded at $21.34 per share. While the registration itself is not a financing event, it signals possible future dilution balanced by improved funding optionality ahead of multiple clinical catalysts.
Tivic Health Systems, Inc. (TIVC) filed an 8-K to disclose that it has entered into an Amended & Restated Exclusive License Agreement (A&R License) with Statera Biopharma covering the TLR5 agonist programs Entolimod and Entolasta. The new agreement fully supersedes the original license executed on 11 Feb 2025.
Key changes versus the February 2025 agreement:
- Royalty flexibility � future royalties may be paid in cash or in Tivic common stock, solely at Tivic’s discretion. This could conserve cash but may cause shareholder dilution if equity is used.
- Directed payments � aside from the original license fee already paid, up to an additional $5.6 million in milestone or other payments owed to Statera will be remitted directly to Avenue Capital on Statera’s behalf.
All other material terms, including Tivic’s worldwide exclusivity for the Acute Radiation Syndrome indication and its option on additional indications (Lymphocyte Exhaustion, Immunosenescence, Neutropenia, Vaccine Adjuvant), remain unchanged.
Strategic implications: The amended structure preserves Tivic’s strategic control of a potentially high-value immunomodulatory asset while improving liquidity management through optional equity settlement. However, the commitment to fund up to $5.6 million—whether in cash or shares—represents a meaningful obligation for a micro-cap issuer and may introduce dilution or leverage pressure depending on financing choices.
Tivic Health Systems (NASDAQ:TIVC), an emerging growth company, filed an 8-K announcing the completion of their Optimization Study for a non-invasive vagus nerve stimulation device. The announcement was made via press release on June 25, 2025. The filing is being furnished under Regulation FD disclosure rules and includes standard forward-looking statements disclaimers. The company's interim CFO, Lisa Wolf, signed the filing.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
What is the core focus of Tivic Health Systems Inc?
How does ClearUP Sinus Relief work?
What distinguishes Tivic Health Systems Inc from traditional pharmaceutical approaches?
Who can benefit from Tivic Health Systems Inc's products?
What is bioelectronic medicine?
How does Tivic Health Systems Inc ensure the safety and quality of its products?
